查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2146902

Montelukast sodium顆粒市場：全球市場預測，2026-2032年

Montelukast Sodium Granules Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Montelukast sodium顆粒市場規模將達到 13.1121 億美元，複合年成長率為 11.26%。

主要市場統計數據
基準年 2025 6.2121億美元
預計年份：2026年 6.8247億美元
預測年份 2032 1,311,210,000 美元
複合年成長率 (%) 11.26%

Montelukast sodium顆粒：概述

Montelukast sodium顆粒劑是一種口服劑型，用於兒童呼吸系統治療，特別適用於吞嚥藥片困難的情況。其臨床意義與Montelukast作為白三烯受體拮抗劑治療氣喘和過敏性鼻炎的既定作用密切相關。市場需求受兒童處方習慣、監管要求、看護者偏好以及適齡劑型供應情況的影響。臨床應用應遵循已批准的適應症和最新的安全指南，包括注意美國藥品包裝盒上關於嚴重神經精神疾病的警告資訊。

兒童製劑的需求正在改變呼吸系統治療的進行方式。

目前，藥物製劑的發展趨勢是更重視兒童用藥的準確性、易吞嚥性和依從性。顆粒劑可以直接服用，也可以根據產品說明與核准的軟性食物混合服用，有助於解決兒童用藥方面的難題。同時，監管機構和臨床醫生更加重視獲益風險評估、在過敏性鼻炎中的合理用藥、藥物安全監測、供應連續性以及為看護者提供清晰的指導。這些變化有利於那些能夠平衡製劑可靠性和​​提供全面患者資訊的製藥公司和醫療保健系統。

人工智慧可以增強在安全、品質和供應方面的決策能力。

人工智慧 (AI) 可以透過從大規模藥物安全監測數據中識別潛在的安全訊號、改進不利事件說明的審查以及協助確定臨床評估病例的優先順序來支持該市場。在製造業領域，機器學習工具可以輔助進行製程監控、偏差檢測、目視檢查和預測性維護，前提是必須維持檢驗的控制措施和手動監督。人工智慧還可以幫助改善需求計劃和庫存管理，但其產出必須透過書面檢驗、資料品管、網路安全措施以及遵守適用的藥品法規進行管理。

地區差異反映了法規、醫療服務取得和兒童醫療保健實踐方面的差異。

北美地區的特點是監管嚴格，對藥物監測要求高，且人們對Montelukast神經精神安全性的認知不斷提高。在拉丁美洲，由於監管途徑多樣，公共和私人醫療資源獲取水平參差不齊，因此本地註冊、分銷穩定性以及看護者教育至關重要。在歐洲，人們強調統一的科學標準，以及國家健保報銷體系和處方規範。在中東，儘管一些市場擁有先進的醫療基礎設施，但對進口的依賴程度很高，各國之間的取得途徑也存在差異。非洲面臨供應不均衡、醫療系統能力有限、兒童用藥實務教育不足等問題。亞太地區法規環境多樣，兒童人口眾多，對本地適用、品質有保證的口服製劑的需求日益成長。

經濟和安全相關的群體正在為每個群體創造不同的商業環境。

在東協市場，儘管有區域合作，但仍需注意各國在註冊要求、採購系統和語言需求上的差異。金磚國家成員國由於監管成熟度、生產能力和公共衛生優先事項各不相同，因此需要製定針對特定國家的合規應對措施和供應計劃。歐盟受益於協調一致的法律規範，但各國在報銷體系和臨床實務方面仍有差異。七國集團市場通常對品質、安全性和實證醫學有嚴格的要求，並期望風險溝通透明化。海灣合作理事會國家通常依賴協調採購和進口藥品，但與當地法規保持一致仍然至關重要。雖然北約成員國並非統一的藥品市場，但它們對衛生安全和供應韌性的通用重視可能會影響其業務永續營運計畫和關鍵藥品儲備計畫。

各國優先事項差異很大，從提供安全資訊到確保當地居民能夠獲得訊息，不一而足。

澳洲重視藥品監管框架和為兒童提供安全資訊。巴西擁有大規模的公共醫療保健系統，並有其獨特的註冊和採購考量。加拿大要求考慮聯邦監管預期和雙語資訊提供。中國市場受不斷變化的監管標準、國內生產能力和區域可及性差異的影響。法國、德國、義大利和西班牙均在歐洲框架內運作，但在處方、報銷和採購趨勢方面各有其獨特之處。印度擁有龐大的藥品生產能力，但醫療保健覆蓋範圍和監管實施情況各不相同。日本高度重視兒童的品質、標示和臨床適用性。墨西哥要求考慮國內報名手續以及公私混合的藥品分銷系統。俄羅斯擁有其自身的監管和供應環境，需要進行本地化的合規性評估。韓國重視嚴格的品質標準和先進的醫療保健服務系統。英國脫歐後仍維持自身的監管和報銷環境。美國特別重視在包裝上發布警告訊息、按照適應症使用產品以及持續監測不利事件。

優先考慮配方品質、負責任的使用和供應穩定性。

產業領導企業必須在產品整個生命週期中保持顆粒檢驗性、劑量準確性、穩定性、包裝性能和污染控制方面的有效性。此外，標籤和教育材料必須與最新的監管安全資訊保持一致，尤其要關注神經精神風險，並提供清晰的給藥和儲存說明。區域策略應根據註冊、報銷、採購和語言要求進行調整，而非一概而論。供應鏈計畫應盡可能認證多個供應商，監控關鍵原料，並利用數據驅動的早期警報系統來應對供應中斷。最後，各組織應僅在檢驗且可審計的工作流程中應用人工智慧，並透過品質、合規性、安全報告和服務連續性等指標來衡量結果。

調查方法：對監管、臨床和供應方證據進行三角檢驗。

本執行摘要對產品類型、其兒童製劑特性、既定的治療背景以及已記錄的監管安全性考慮進行了結構化的定性回顧。分析涵蓋六個主要區域、六個經濟和安全組別以及15個國家，並著重指出了在獲取途徑、監管、醫療服務和營運要求方面的差異。此方法優先考慮權威的監管公告、已通過核准的產品資訊、臨床指南、同行評審的證據以及公開記錄的藥品品質原則。本摘要未使用任何市場估算、預測、市場佔有率、預期或公司特定聲明。在做出任何營運或醫療決策之前，應根據當前的國家附加檔、監管決定和當地臨床指南對這些發現進行檢驗。

負責任的實施將決定該類別的下一階段。

Montelukast sodium顆粒劑在兒童呼吸系統護理領域佔據著重要的細分市場，因為它解決了傳統固態口服劑型無法解決的給藥難題。然而，要使其持續得到應用，需要嚴格的患者篩選、透明的安全資訊傳播、穩定的產品品質以及可靠的獲取途徑。考慮到地區和國家的具體差異，需要製定本地化的法規和醫療保健策略，而人工智慧只有在經過檢驗的數據和負責任的人工審核的支持下才能發揮其價值。整合這些優先事項的領導者可以在不高估藥物作用或忽視既定安全考量的前提下，提升以病人為中心的用藥模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：Montelukast sodium顆粒市場：依病患年齡層別分類

  • 成人
  • 兒童
    • 2-5歲
    • 6至14歲

第8章：Montelukast sodium顆粒市場：依劑量強度分類

  • 4毫克
  • 5毫克

第9章：Montelukast sodium顆粒市場：依應用領域分類

  • 氣喘
  • 運動誘發支氣管收縮
  • 常年性過敏性鼻炎
  • 季節性過敏性鼻炎

第10章：Montelukast sodium顆粒市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：Montelukast sodium顆粒市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第12章：Montelukast sodium顆粒市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：Montelukast sodium顆粒市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：Montelukast sodium顆粒市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Amneal Pharmaceuticals, Inc..
  • Apotex Inc
  • Aurobindo Pharma Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd..
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd..
  • Merck & Co., Inc.
  • Sandoz Inc.
  • Sanofi SA.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Viatris Inc.

第17章 主要專家

Product Code: MRR-3D150775E48B

The Montelukast Sodium Granules Market is projected to grow by USD 1,311.21 million at a CAGR of 11.26% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 621.21 million
Estimated Year [2026] USD 682.47 million
Forecast Year [2032] USD 1,311.21 million
CAGR (%) 11.26%

Montelukast Sodium Granules: Executive Overview

Montelukast sodium granules are an oral dosage form used in pediatric respiratory care, particularly where swallowing tablets is difficult. Their clinical relevance is linked to montelukast's established role as a leukotriene receptor antagonist for asthma and allergic rhinitis. Demand conditions are shaped by pediatric prescribing practices, regulatory requirements, caregiver preferences, and the availability of age-appropriate formulations. Clinical use should follow approved indications and current safety guidance, including attention to the product's boxed warning regarding serious neuropsychiatric events in the United States.

Pediatric Formulation Needs Are Reshaping Respiratory Treatment

The landscape is shifting toward formulations that support accurate administration, easier swallowing, and adherence among children. Granules can be administered directly or mixed with approved soft foods, subject to product instructions, which may help address pediatric usability challenges. At the same time, regulators and clinicians are placing greater emphasis on benefit-risk assessment, responsible use in allergic rhinitis, pharmacovigilance, supply continuity, and clear caregiver counseling. These changes favor manufacturers and healthcare systems that combine formulation reliability with strong patient-information practices.

Artificial Intelligence Strengthens Safety, Quality, and Supply Decisions

Artificial intelligence can support this market by identifying potential safety signals from large-scale pharmacovigilance data, improving review of adverse-event narratives, and helping prioritize cases for clinical assessment. In manufacturing, machine-learning tools may assist process monitoring, deviation detection, visual inspection, and predictive maintenance, provided that validated controls and human oversight remain in place. AI can also improve demand planning and inventory monitoring, but its outputs should be governed through documented validation, data-quality controls, cybersecurity safeguards, and compliance with applicable pharmaceutical regulations.

Regional Differences Reflect Regulation, Access, and Pediatric Care Practices

North America is characterized by formal regulatory scrutiny, strong pharmacovigilance expectations, and heightened awareness of montelukast's neuropsychiatric safety communication. Latin America presents varied regulatory pathways and differences in public and private access, making local registration, distribution resilience, and caregiver education important. Europe emphasizes harmonized scientific standards alongside national reimbursement and prescribing practices. The Middle East combines advanced healthcare infrastructure in some markets with import dependence and access variation across countries. Africa faces uneven availability, health-system capacity constraints, and the need for practical pediatric dosing education. Asia-Pacific includes diverse regulatory environments, substantial pediatric populations, and growing attention to locally appropriate, quality-assured oral formulations.

Economic and Security Groupings Create Distinct Operating Contexts

ASEAN markets require attention to differing national registrations, procurement systems, and language needs despite regional cooperation. BRICS members span varied regulatory maturity, manufacturing capabilities, and public-health priorities, making country-specific compliance and supply planning essential. The European Union benefits from coordinated regulatory structures while retaining national differences in reimbursement and clinical practice. G7 markets generally maintain demanding quality, safety, and evidence requirements, with strong expectations for transparent risk communication. GCC countries often depend on coordinated procurement and imported medicines, while local regulatory alignment remains important. NATO members do not constitute a unified pharmaceutical market, but their overlapping emphasis on health security and supply resilience can influence continuity planning and critical-medicine preparedness.

Country-Level Priorities Range from Safety Communication to Local Access

Australia emphasizes a regulated medicines framework and pediatric safety communication. Brazil combines a large public health system with country-specific registration and procurement considerations. Canada requires attention to federal regulatory expectations and bilingual communication. China's market is shaped by evolving regulatory standards, domestic manufacturing capacity, and regional access differences. France, Germany, Italy, and Spain operate within the European framework but retain distinct prescribing, reimbursement, and procurement dynamics. India combines broad pharmaceutical manufacturing capabilities with varied healthcare access and regulatory implementation. Japan places strong emphasis on quality, labeling, and pediatric clinical appropriateness. Mexico requires navigation of national registration and mixed public-private distribution. Russia presents a distinct regulatory and supply environment requiring localized compliance assessment. South Korea emphasizes rigorous quality standards and advanced healthcare delivery. The United Kingdom maintains a separate post-EU regulatory and reimbursement context. The United States places particular importance on boxed-warning communication, indication-specific use, and ongoing adverse-event monitoring.

Prioritize Formulation Quality, Responsible Use, and Supply Resilience

Industry leaders should maintain validated granule uniformity, dose accuracy, stability, packaging performance, and contamination controls across the product lifecycle. They should align labeling and educational materials with current regulatory safety communications, especially for neuropsychiatric risks, and provide clear instructions for administration and storage. Regional strategies should be adapted to registration, reimbursement, procurement, and language requirements rather than treated as interchangeable. Supply-chain programs should qualify multiple sources where feasible, monitor critical materials, and use data-driven early-warning systems for disruption. Finally, organizations should apply AI only within validated, auditable workflows and measure outcomes through quality, adherence, safety-reporting, and service-continuity indicators.

Methodology: Triangulating Regulatory, Clinical, and Supply-Side Evidence

This executive summary uses a structured qualitative review of the product category, its pediatric formulation characteristics, established therapeutic context, and documented regulatory safety considerations. Analysis is organized across six required regions, six economic or security groupings, and fifteen countries to identify differences in access, oversight, healthcare delivery, and operational requirements. The approach prioritizes authoritative regulatory communications, approved product information, clinical guidance, peer-reviewed evidence, and publicly documented pharmaceutical-quality principles. No market estimates, market shares, forecasts, or company-specific claims are used. Findings should be validated against current national labeling, regulatory decisions, and local clinical guidance before operational or medical decisions are made.

Responsible Execution Will Define the Category's Next Stage

Montelukast sodium granules occupy an important niche in pediatric respiratory treatment because they address administration challenges that conventional solid oral forms may not. However, sustainable adoption depends on disciplined patient selection, transparent safety communication, consistent product quality, and dependable access. Regional and country differences require localized regulatory and healthcare strategies, while AI can add value only when supported by validated data and accountable human review. Leaders that integrate these priorities can strengthen patient-centered use without overstating the medicine's role or overlooking its established safety considerations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Montelukast Sodium Granules Market, by Patient Age Group

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Pediatric
    • 7.3.1. 2 To 5 Years
    • 7.3.2. 6 To 14 Years

8. Montelukast Sodium Granules Market, by Dosage Strength

  • 8.1. Introduction
  • 8.2. 4 Milligram
  • 8.3. 5 Milligram

9. Montelukast Sodium Granules Market, by Application

  • 9.1. Introduction
  • 9.2. Asthma
  • 9.3. Exercise Induced Bronchoconstriction
  • 9.4. Perennial Allergic Rhinitis
  • 9.5. Seasonal Allergic Rhinitis

10. Montelukast Sodium Granules Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Montelukast Sodium Granules Market, by End User

  • 11.1. Introduction
  • 11.2. Clinic
  • 11.3. Home Care
  • 11.4. Hospital

12. Montelukast Sodium Granules Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Montelukast Sodium Granules Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Montelukast Sodium Granules Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Amneal Pharmaceuticals, Inc.
  • 16.2. Apotex Inc
  • 16.3. Aurobindo Pharma Ltd.
  • 16.4. Cipla Limited
  • 16.5. Dr. Reddy's Laboratories Ltd.
  • 16.6. Glenmark Pharmaceuticals Ltd.
  • 16.7. Intas Pharmaceuticals Ltd..
  • 16.8. Lupin Limited
  • 16.9. Macleods Pharmaceuticals Ltd..
  • 16.10. Merck & Co., Inc.
  • 16.11. Sandoz Inc.
  • 16.12. Sanofi S.A..
  • 16.13. Sun Pharmaceutical Industries Ltd.
  • 16.14. Teva Pharmaceuticals USA, Inc.
  • 16.15. Viatris Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Montelukast Sodium Granules Market, Years Considered for the Study
  • FIGURE 2. Global Montelukast Sodium Granules Market, Research Design
  • FIGURE 3. Global Montelukast Sodium Granules Market, Research Framework
  • FIGURE 4. Global Montelukast Sodium Granules Market, Data Triangulation
  • FIGURE 5. Global Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Montelukast Sodium Granules Market Size, by Patient Age Group, 2025 vs 2032 (%)
  • FIGURE 7. Global Montelukast Sodium Granules Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Montelukast Sodium Granules Market Size, by Dosage Strength, 2025 vs 2032 (%)
  • FIGURE 9. Global Montelukast Sodium Granules Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Montelukast Sodium Granules Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global Montelukast Sodium Granules Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Montelukast Sodium Granules Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Montelukast Sodium Granules Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Montelukast Sodium Granules Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Montelukast Sodium Granules Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Montelukast Sodium Granules Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Montelukast Sodium Granules Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Montelukast Sodium Granules Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Montelukast Sodium Granules Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Montelukast Sodium Granules Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Montelukast Sodium Granules Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Montelukast Sodium Granules Market Segmentation & Coverage
  • TABLE 2. Global Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 4. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global 2 To 5 Years Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global 2 To 5 Years Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global 2 To 5 Years Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global 6 To 14 Years Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global 6 To 14 Years Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global 6 To 14 Years Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 17. Global 4 Milligram Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global 4 Milligram Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global 4 Milligram Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global 5 Milligram Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global 5 Milligram Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global 5 Milligram Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 24. Global Asthma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Asthma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Asthma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Exercise Induced Bronchoconstriction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Exercise Induced Bronchoconstriction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Exercise Induced Bronchoconstriction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Perennial Allergic Rhinitis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Perennial Allergic Rhinitis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Perennial Allergic Rhinitis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Seasonal Allergic Rhinitis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Seasonal Allergic Rhinitis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Seasonal Allergic Rhinitis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 37. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 47. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Asia-Pacific Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Asia-Pacific Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 59. Asia-Pacific Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 60. Asia-Pacific Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 61. Asia-Pacific Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 62. Asia-Pacific Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 63. Asia-Pacific Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 64. North America Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. North America Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 66. North America Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 67. North America Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 68. North America Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 69. North America Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 70. North America Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. Latin America Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Latin America Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 73. Latin America Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 74. Latin America Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 75. Latin America Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 76. Latin America Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 77. Latin America Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 78. Europe Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Europe Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 80. Europe Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 81. Europe Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 82. Europe Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 83. Europe Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 84. Europe Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 85. Middle East Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Middle East Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 87. Middle East Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 88. Middle East Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 89. Middle East Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 90. Middle East Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 91. Middle East Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 92. Africa Montelukast Sodium Granules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Africa Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 94. Africa Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 95. Africa Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 96. Africa Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 97. Africa Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 98. Africa Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 99. Global Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. ASEAN Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. ASEAN Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 102. ASEAN Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 103. ASEAN Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 104. ASEAN Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 105. ASEAN Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 106. ASEAN Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 107. GCC Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. GCC Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 109. GCC Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 110. GCC Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 111. GCC Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 112. GCC Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 113. GCC Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. European Union Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. European Union Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 116. European Union Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 117. European Union Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 118. European Union Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. European Union Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 120. European Union Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. BRICS Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. BRICS Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 123. BRICS Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 124. BRICS Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 125. BRICS Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 126. BRICS Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 127. BRICS Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 128. G7 Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 129. G7 Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 130. G7 Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 131. G7 Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 132. G7 Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 133. G7 Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. G7 Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. NATO Montelukast Sodium Granules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 136. NATO Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 137. NATO Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 138. NATO Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 139. NATO Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 140. NATO Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 141. NATO Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. Global Montelukast Sodium Granules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 143. United States Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 144. United States Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 145. United States Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 146. United States Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 147. United States Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 148. United States Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 149. United States Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. Canada Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 151. Canada Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 152. Canada Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 153. Canada Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 154. Canada Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 155. Canada Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 156. Canada Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 157. Mexico Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 158. Mexico Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 159. Mexico Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 160. Mexico Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 161. Mexico Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 162. Mexico Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 163. Mexico Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 164. Brazil Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 165. Brazil Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 166. Brazil Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 167. Brazil Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 168. Brazil Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 169. Brazil Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. Brazil Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 171. United Kingdom Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 172. United Kingdom Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 173. United Kingdom Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 174. United Kingdom Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 175. United Kingdom Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 176. United Kingdom Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 177. United Kingdom Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 178. Germany Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 179. Germany Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 180. Germany Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 181. Germany Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 182. Germany Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 183. Germany Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 184. Germany Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. France Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 186. France Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 187. France Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 188. France Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 189. France Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 190. France Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. France Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 192. Russia Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 193. Russia Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 194. Russia Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 195. Russia Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 196. Russia Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 197. Russia Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 198. Russia Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. Italy Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 200. Italy Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 201. Italy Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 202. Italy Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 203. Italy Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 204. Italy Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. Italy Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 206. Spain Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 207. Spain Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 208. Spain Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 209. Spain Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 210. Spain Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 211. Spain Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 212. Spain Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 213. China Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 214. China Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 215. China Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 216. China Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 217. China Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 218. China Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 219. China Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 220. India Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 221. India Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 222. India Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 223. India Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 224. India Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 225. India Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 226. India Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 227. Japan Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 228. Japan Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 229. Japan Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 230. Japan Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 231. Japan Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 232. Japan Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 233. Japan Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 234. Australia Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 235. Australia Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 236. Australia Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 237. Australia Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 238. Australia Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 239. Australia Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 240. Australia Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 241. South Korea Montelukast Sodium Granules Market Size, 2017-2032 (USD Million)
  • TABLE 242. South Korea Montelukast Sodium Granules Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 243. South Korea Montelukast Sodium Granules Market Size, by Pediatric, 2017-2032 (USD Million)
  • TABLE 244. South Korea Montelukast Sodium Granules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 245. South Korea Montelukast Sodium Granules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 246. South Korea Montelukast Sodium Granules Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 247. South Korea Montelukast Sodium Granules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 248. Global Montelukast Sodium Granules Market Share, by Key Player, 2025
  • TABLE 249. Global Montelukast Sodium Granules Market, Key Experts